TY - JOUR
T1 - Commentary on Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B
T2 - Role in D2 receptor function
AU - Lee, Hun Joo
AU - Rodriguez-Contreras, Dayana
AU - Neve, Kim A.
N1 - Publisher Copyright:
© 2021 American Society for Pharmacology and Experimental Therapy. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - We previously proposed that the dopamine D2 receptor-interacting protein S100B binds to a putative S100B-binding motif at residues R233-L240 toward the N terminus of the third intracellular loop. We used in vitro pull-down assays with FLAG-tagged fragments of the rat dopamine D2 receptor third intracellular loop (D2-IC3) and in vitro-synthesized S100B to evaluate this hypothesis. Our results indicate that the putative S100B-binding motif is neither necessary nor sufficient for strong binding of S100B to D2-IC3. Instead, two residues at the junction of the fifth membrane-spanning domain and the cytoplasmic extension of that α-helical domain, K211-I212, are required for robust, calcium-sensitive binding of S100B. This is also the approximate location of previously identified determinants for the binding of arrestin and calmodulin. A D2 receptor mutation converting I212 to phenylalanine has been described in patients with a hyperkinetic movement disorder. SIGNIFICANCE STATEMENT S100B is a small calcium-binding protein that modulates signaling by the dopamine D2 receptor. New data suggest that the previous hypothesis about the involvement of an S100B-binding motif is incorrect, and that an important determinant of S100B binding includes a residue that is mutated in patients with a hyperkinetic movement disorder.
AB - We previously proposed that the dopamine D2 receptor-interacting protein S100B binds to a putative S100B-binding motif at residues R233-L240 toward the N terminus of the third intracellular loop. We used in vitro pull-down assays with FLAG-tagged fragments of the rat dopamine D2 receptor third intracellular loop (D2-IC3) and in vitro-synthesized S100B to evaluate this hypothesis. Our results indicate that the putative S100B-binding motif is neither necessary nor sufficient for strong binding of S100B to D2-IC3. Instead, two residues at the junction of the fifth membrane-spanning domain and the cytoplasmic extension of that α-helical domain, K211-I212, are required for robust, calcium-sensitive binding of S100B. This is also the approximate location of previously identified determinants for the binding of arrestin and calmodulin. A D2 receptor mutation converting I212 to phenylalanine has been described in patients with a hyperkinetic movement disorder. SIGNIFICANCE STATEMENT S100B is a small calcium-binding protein that modulates signaling by the dopamine D2 receptor. New data suggest that the previous hypothesis about the involvement of an S100B-binding motif is incorrect, and that an important determinant of S100B binding includes a residue that is mutated in patients with a hyperkinetic movement disorder.
UR - http://www.scopus.com/inward/record.url?scp=85109468819&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109468819&partnerID=8YFLogxK
U2 - 10.1124/molpharm.121.000284
DO - 10.1124/molpharm.121.000284
M3 - Review article
C2 - 34045267
AN - SCOPUS:85109468819
SN - 0026-895X
VL - 100
SP - 61
EP - 64
JO - Molecular pharmacology
JF - Molecular pharmacology
IS - 2
ER -